Day: May 7, 2021

CALGARY, Alberta, May 07, 2021 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company“), a leading developer of spectroscopy-based technology, is pleased to announce that, further to its news release dated April 12, 2021, it has received TSX Venture Exchange (the “Exchange“) approval to extend the exercise the period of the Company’s Early Warrant Exercise Incentive Program (“EWEIP“) intended to encourage the early exercise of up to 18,550,000 Warrants (as defined and described below) from May 7, 2021 to May 12, 2021, as further described below. In January of 2021, FluroTech closed, in two tranches, a non-brokered private placement of units (“Units“), for aggregate gross proceeds of $2,531,000. Each Unit comprised one common share in...

NORWALK, Conn., May 07, 2021 (GLOBE NEWSWIRE) — Reed’s Inc. (Nasdaq: REED), owner of the nation’s leading portfolio of handcrafted, all-natural beverages, today announced that it intends to issue its financial results for the first quarter ended March 31, 2021 after the market close on Monday, May 17, 2021. Following the release, members of Reed’s, Inc. senior management team will host a conference call with financial analysts and investors at 4:30 p.m. Eastern Time. This conference call can be accessed via a link on Reed’s investor website at https://investor.reedsinc.com under the “Events & Presentations” section or directly at http://public.viavid.com/index.php?id=144910. To listen to the live call over the Internet, please go to Reed’s website at least 15 minutes early to register, download and...

LONDON, May 07, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), an IP-led neuropharmaceutical company, is pleased to announce an update on its patent portfolio since the filing of its filing statement on April 23, 2021. The Company announces that it has received an in order for grant notice in the United Kingdom for one of its patents related to psychedelic tryptamines. This UK patent will be the first one to receive an in order for grant notice from within the Company’s growing patent portfolio for psychedelic-based medicines. The Company has also filed two new patent applications and now has 31 patents pending. Updates to Patent PortfolioThe Company has received notice that its UK patent application GB2008303.6 is in order for grant. This UK patent application will cover a range of N,N-dimethyltryptamine...

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the Q2 Virtual Investor Summit on Tuesday, May 18th at 4:15 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website. A...

All dollar references are in U.S. dollars, unless noted otherwise. BROOKFIELD NEWS, May 07, 2021 (GLOBE NEWSWIRE) — Brookfield Property Partners L.P. (NASDAQ: BPY; NASDAQ: BPYU; TSX: BPY.UN) (“BPY” or the “Partnership”) today announced financial results for the quarter ended March 31, 2021. “While we continue to experience challenges in certain of our operations and markets due to the ongoing consequences of the pandemic and global economic slowdown, we remain encouraged by a recovery in activity in select sectors within our business,” said Brian Kingston, CEO of Brookfield Property Partners. Financial Results Net income for the quarter ended March 31, 2021 was $731 million or $0.25 per LP unit compared to a loss of $373 million or $(0.49) per LP unit for the same period in 2020. This quarter benefited from gains in...

Global design and technology firm collaborates with automotive giant to transform its R&E facility into an innovation center SOUTHFIELD, Mich., May 07, 2021 (GLOBE NEWSWIRE) — Global design and technology firm, IBI Group (TSX: IBG), is lead architect on Ford Motor Company’s new Research & Engineering Center which is set to centralize Ford’s operations in Michigan and support increased innovation and collaboration. IBI Group is leading the project’s architecture, engineering, and landscape design in partnership with Snøhetta and Ghafari Associates. The firm’s expertise in technology-driven design, coupled with its smart cities portfolio, is contributing to the world-class transformation of Ford’s Dearborn Campus. The facility is expected to further establish Ford’s competitive edge in the future of mobility, and is set...

Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in an animal model of PXE BOSTON, May 07, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical development candidate, INZ-701, as a potential treatment for ABCC6 Deficiency. The data, presented at the virtual European Calcified Tissue Society Annual Congress (ECTS, May 6-8), are the first to show that an enzyme replacement therapy (ERT) increased plasma pyrophosphate (PPi) levels and reduced calcification in an animal model of ABCC6 Deficiency. ABCC6...

MONTREAL, May 07, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2021 financial results on Friday, May 14, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Friday, May 14, 2021 Time: 8:30 a.m. ET Telephone: Toll Free: 888-506-0062 or International 973-528-0011 Webcast: www.gud-knight.com or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay: An archived replay will be available for 30 days at www.gud-knight.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty...

DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2021 financial results before the open of the U.S. financial markets on Friday, May 14, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business. To register for the conference call please use this link: https://www.incommglobalevents.com/registration/client/7304/iterum-therapeutics-1st-quarter-2021-financial-results-conference-call/.    After registering, a confirmation...